COVAXIN 77.8% effective against coronavirus in Lancet study
Image Credit: zee5
COVAXIN's safety and efficacy data has been peer-reviewed and published in The Lancet medical journal, confirming the vaccine is 77.8% effective against COVID-19. This comes four months after the company revealed similar findings in a published pre-print study. COVAXIN is India's first indigenous vaccine against the coronavirus and is one of the six vaccines that have been approved in the country.